Virtual Library

Start Your Search

nadia Benchakroun



Author of

  • +

    EP1.01 - Advanced NSCLC (ID 150)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.01-102 - Efficacy and Toxicity of Erlotinib and Gefitinib in Moroccan Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation (Now Available) (ID 1926)

      08:00 - 18:00  |  Presenting Author(s): nadia Benchakroun

      • Abstract
      • Slides

      Background

      BACKGROUND

      Lung cancer, the second most common cancer in Morocco, is a public health problem.

      It is also the leading cause of cancer death in the world because its prognosis is poor and the diagnosis is often made at a metastatic stage.

      The advent of tyrosine kinase inhibitors has improved survival in patients with epidermal growth factor receptor mutation (EGFR)

      There are few studies in Morocco, the aim of this study was to evaluate the efficacy and safety of anti-EGFR in patients with non-small cell lung cancer with EGFR mutated in Morocco.

      Method

      METHODS

      We had collected twenty-three patients followed for metastatic non-small cell lung cancer with EGFR mutation and management in the onco-radiotherapy department of the IBN ROCHD University Hospital of Casablanca (MOROCCO)

      Result

      RESULTS

      Of the twenty-three patients collected, the sex ratio was 7 men to 16 women, the average age was 59 years, only one case had a history of smoking, all cases had adenocarcinoma, the mutation on exon 19 was found in 87%.

      The median progression-free survival was 4 months and the median overall survival was 12 months,

      For tolerance; diarrhea and folliculitis were found in all patients with 50% grade II.

      Conclusion

      CONCLUSIONS

      The EGFR mutation appears to be more frequent in women and non-smokers, and anti-EGFR treatment improves survival with a particular tolerance profile that should be known.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    EP1.14 - Targeted Therapy (ID 204)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Targeted Therapy
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.14-40 - Locally Advanced Desmoide Tumor: Response to Sorafenib: Case Report (Now Available) (ID 1140)

      08:00 - 18:00  |  Presenting Author(s): nadia Benchakroun

      • Abstract
      • Slides

      Background

      Desmoid tumors or deep fibromatoses are malignant connective clonal tissue tumors that do not metastasize, but are at high risk of local recurrence and are associated with morbidity and mortality. There is still no standard for treatment, however the reactions of patients with desmoid tumors with Sorafenib are promising. The objective of this work is to highlight the contribution of sorafenib in the treatment of desmoid tumors.

      Method

      Our study is a case report conducted in the oncology department of IBN ROCHD CHU of Casablanca, focusing on the analysis of the Sorafenib response in patient with locally advanced desmoid tumor.

      Result

      Our case is a 60-year-old patient with no comorbidities who had presented in 2012 a left dorsal parietal mass, he was operated on, the histopathological examination concluded to a desmoid tumor. He presented in 2015 a tumor recurrence for which he was again operated and put under Celecoxib for one year, after the clinical and radiological progression, he was put under Tamoxifen, for 2 years. Currently, he presents a tumor increase. In fact he has a posterior dorso lumbar parietal mass, measuring clinically about 15 cm, very painful, the initial thoracic CT scan as well as the MRI of the soft tissues showed left lateral vertebral parietal mass, hypodense coming into contact with the last 3 ribs without bone lysis, measuring 12 * 11 * 7 cm. The surgery was considered dilapidated by the surgeons, the decision was to put the patient under Sorafenib 400 mg per day, the assessment after two months found an excellent clinical and radiological response, with a total disappearance of pain and 50% decrease in the size of the initial injury on the chest CT scan.

      Conclusion

      This case study allowed us to support the efficacy of Sorafenib, currently being tested (Study Alliance A91105) in the treatment of recurrent or locally advanced desmoid tumors.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    EP1.15 - Thymoma/Other Thoracic Malignancies (ID 205)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Thymoma/Other Thoracic Malignancies
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.15-10 - Survival Impact of Non-Surgical Treatment in Thymic Epithelial Tumours: A Retrospective Study (Now Available) (ID 724)

      08:00 - 18:00  |  Presenting Author(s): nadia Benchakroun

      • Abstract
      • Slides

      Background

      The management of thymic epithelial tumours, although poorly defined due to their rarity, remains multidisciplinary in order to offer patients multimodal treatment with surgery as the therapeutic pillar.

      Our main objective is to highlight the impact of non-surgical treatments on the overall survival and the progression free survival of patients treated for these tumours at the Mohamed VI center.

      Method

      We carried out a monocentric, descriptive and retrospective study using databases from the oncology, the thoracic surgery and anatomopathology departments of the Ibn Rochd University Hospital in Casablanca.

      We identified all patients with thymoma or thymic carcinoma whose histological diagnosis was made on a biopsy or a surgical excision piece between July 2006 and February 2016

      After exclusions, 42 patients were identified and we used a farm sheet to specify for each patient, epidemiological data, data related to histological type, Masaoka-Koga staging and progress under treatment (complete or partial response, stabilization or progression)

      For our analysis, we used Microsoft Office, Excel 2007 and Kaplan Meier Software to assess overall ans progression free survival.

      Result

      42 cases of thymic epithelial tumours were reported between 2006 and 2016 with apredominance of type B1 in patients aged between 25 and 77 years.

      The radiological assessment carried out before treament showed that 9.5% of the diseases were metastatic from the outset, while the others had an intra – thoracic locoregional extension

      Half of the patients were resectable from the outset, wich made it possible to perform primary surgery leading to carcinological resection with generally simple post-operative outcomes.

      In our series, CAP D1 = D21 chemotherapy was the preferred regimen to be indicated as a pre operative treatment to reduce the size of the tumor and increase its resectivity rate in 11 patients (26,2% of cases). This chemotherapy was indicated as adjuvant treatment in 06 cases of incomplete resection (14,3% of cases)

      Two patients (4,8% of cases) received first chemotherapy followed by exclusive radiation therapy at 66 Gy while more than 25% received a post-operative radiation therapy at variable doses ranging from 50-54Gy for R0 tumours or microscopic disease to 60-70Gy for macroscopic disease.

      The overall and progression free survivals at 22 months were 94,6% and 68,4% respectively.

      The prognostic factors are, in univariate analysis, the performans status, the histological type, the Masaoka-Koga stage and the quality of surgical resection.

      The multivariate analysis could not be performed due to a lack of statistical power, due to the small number of patients and the retrospective nature of the study.

      Conclusion

      The thymic epithelial tumours treatment is a real challenge given the absence of randomized prospective studies on this subject

      Surgery remains the mainstay of management but neo-adjuvant and or adjuvant treatments can be considered in case of poor prognostic factors in order to reduce the risk of recurrence or death from the disease.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Treatment in the Real World - Support, Survivorship, Systems Research
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.16-09 - Delays in Care of Lung Cancer: A Moroccan Public Health Problem (Now Available) (ID 1909)

      08:00 - 18:00  |  Presenting Author(s): nadia Benchakroun

      • Abstract
      • Slides

      Background

      For several years, lung cancer, which is responsible for one in five cancer deaths, has been considered the leading cause of cancer death.

      In Morocco, in 2018, 6488 new cases of lung cancer were reported for both sexes and all ages with 22,9% of all new cases of male cancer (Globocan)

      It’s a real public health problem

      The delay between the different therapeutic sequences has a real impact on survival, which makes it’s optimization a real public health issue.

      The aim of this work was to describe the care pathway for patients treated for lung cancer at the Mohamed VI Center, as well as the different treatment delays in our context.

      Method

      To do this, we conducted a monocentric, retrospective study in patients treated for lung cancer between January 2012 and November 2017 at the Mohamed VI Cancer treatment Center.

      To study this period and obtain significant results, we referred to the statistical rules and retained one month pey year, one year out of two, for a total of six months spread between January 2012 and November 2017

      Using the oncology department’s database, we identified all patients with histologically confirmed lung cancer and a usable archived record that was summarized in a farm with pre-established responses coded as numerical variables.

      The key point of this study was the study of the time between the appearance of the first clinical signs and the initiation of the different therapeutic sequences discussed in a multidisciplinary meeting.

      Result

      During the study period, 125 cases of lung cancer were collected. The average age was 57,6 years

      The average consult time also called patient time was 3.92 months.

      As for the delays related to the health system there are :

      An average diagnostic time of 63,5 days

      A therapeutic delay of 67,9 days on average

      An average overall delay of 216,3 days

      The time to diagnosis was therefore close to that recommended by the littérature, while the consultation, treatment and overall time to diagnosis were longer which significantly affects the survival curve

      Conclusion

      In several countries, delays in care and access to care services, considered as indicators of system performance, have become a priority in public health policies.

      The establishment of more specialized oncology and radiation oncology centers should help to reduce them

      A subsequent reassessment of these delays, after correction, will male it possible to assess the evolution of the quality of the managementof this cancet at the Mohamed VI center

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.04 - Immuno-oncology (ID 167)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.04-29 - Association of Inflammation Related Genes with Lung Cancer Risk in Moroccan Population (ID 2413)

      10:15 - 18:15  |  Author(s): nadia Benchakroun

      • Abstract

      Background

      Lung cancer is known to be a complex multifactorial disease involving both genetic and environmental factors. The study of different signaling pathways and identification of the genes involved, will contribute to further understanding the pathogenesis of the disease, thus allowing the development of appropriate targeted treatments and even a prevention strategies. The inflammation caused by immune system activation is likely linked to carcinogenesis by promoting angiogenesis and proliferation of tumour cells , according to the cytokine profile in the tumour microenvironment. Previous studies have suggested that key cytokines in inflammation pathways may have an important roles in the etiology of lung cancer. The aim of this study was to investigate whether common inflammation related genes influence lung cancer risk in Moroccan population.

      Method

      Single nucleotide polymorphisms (SNPs) in IL-6, IL6-R and IL6-ST, IL6, IL17-A, IL17-F, IL-8, MIF and STAT3 genes were assessed in 150 controls and 150 lung cancer patients. Genotyping was performed with the TaqMan® allelic discrimination technology and RFLP-PCR. Gene expression of cytokines was evaluated in the peripheral blood samples of lung cancer patients and healty controls. Total RNA of the blood cells were extracted and reverse transcribed to cDNA. Screenings of deferentially expressed genes associated with inflammation were performed using real-time PCR.

      Result

      Among the studied SNPs, we found a significant association for the IL-6 (rs2069840), IL-6 (rs1800795), IL-6 (rs1800796), IL-17F (rs763780), IL-17F (rs763780), IL-8 and the MIF (rs755622). No significant association was observed for the remaining SNPs of IL-6R (rs2228145) IL-6ST (rs2228044), IL-17A (rs2275913), IL17A (rs7747909) and STAT3 (rs2293152) genes. Cytokines genes expression revealed significant association with lung cancer. Genes expression were increased in lung cancer patients comparing to healty subjects.

      Conclusion

      Our results suggest the important role of inflammation related genes in the occurrence of lung cancer and cytokines genes associated may be considered as a genetic marker for predisposition to Lung cancer in Moroccan population.